How Personalized mRNA Cancer Vaccines Work

A personalized mRNA cancer vaccine is a treatment for cancer you already have, not a shot to prevent cancer. It is built after a biopsy, when a lab sequences your tumor's DNA, identifies mutations that exist only in the cancer cells, and makes an mRNA drug that trains your immune system to attack those specific mutations.

Is the mRNA cancer vaccine a preventive vaccine or a treatment for existing cancer?

A preventive vaccine is given before disease to stop it from starting. A therapeutic cancer vaccine is given after diagnosis to teach the immune system to reject a cancer that is already growing. Personalized mRNA cancer vaccines fall squarely in the second group.

The confusion is understandable. mRNA vaccines became famous as COVID-19 prevention. But the mRNA in a cancer vaccine is not coding for a virus spike protein. It codes for pieces of protein that are altered by mutations in a patient's own tumor. No tumor, no personalized vaccine. You cannot make one ahead of time.

A personalized mRNA cancer vaccine is a drug built from your own tumor, not a shot you get to prevent cancer.

What gets sequenced: your tumor, not just your inherited DNA

The starting material is a tumor sample, usually from a biopsy or surgery. The lab sequences the tumor DNA and often RNA, then compares it with DNA from blood or saliva to filter out the variants you were born with.

Most of the mutations in a tumor do not change a protein. The ones that do can create neoantigens, short protein fragments that exist on the cancer cell surface and not on healthy cells. The sequencing pipeline looks for those fragments. Algorithms then predict which neoantigens are most likely to be displayed by the patient's own immune proteins, the HLA molecules. The vaccine is built around those.

This is a different use of DNA sequencing than a consumer DNA test. A raw DNA file from 23andMe or AncestryDNA looks at inherited variants in your normal cells. It cannot find tumor mutations, because tumor mutations happen after birth and only in the tumor.

How the immune system gets trained

The vaccine is an injection of mRNA inside lipid nanoparticles. The mRNA encodes a string of selected neoantigens, often 10 to 34 of them in one construct. After injection, cells take up the mRNA and make the neoantigen proteins. Immune cells called dendritic cells process those proteins and present them to T cells.

That presentation is the actual training event. It tells T cells: these protein fragments are foreign, go look for cells carrying them. If the tumor already has those same neoantigens, the activated T cells can recognize and kill the cancer cells.

The mechanism matters because it explains why this is personal. The same vaccine would not be expected to work in another patient. Their tumor has a different set of mutations, and their HLA molecules present different fragments.

What this looks like in real trial data

In the melanoma trial that put this approach on the map, patients with high-risk resected melanoma got either pembrolizumab alone or pembrolizumab plus an mRNA vaccine built from their tumor. In KEYNOTE-942, at 18 months, recurrence-free survival was 78.6 percent in the vaccine group and 62.2 percent in the pembrolizumab-only group. That works out to about a 44 percent lower risk of recurrence or death in that phase 2 trial.

On the practical side, the process is not instant. Tumor sequencing, neoantigen selection, mRNA manufacturing and quality control often take around six to eight weeks from biopsy to first dose. That delay is a real limitation when someone needs treatment quickly.

Side effects in trials have been mostly what you would expect from an immune-stimulating shot: fever, fatigue, muscle aches, and injection site reactions. When combined with checkpoint inhibitors, the checkpoint inhibitor side effects, like thyroid or skin inflammation, are the bigger concern.

Why this is different from preventive cancer vaccines

There are preventive cancer vaccines already in use, and they are not this. The HPV vaccine prevents infection with the virus that causes most cervical cancers and some head and neck cancers. The hepatitis B vaccine lowers the risk of liver cancer by preventing chronic hepatitis B infection. They are given before cancer, and they target a virus, not the tumor itself.

The simple answer has one edge case worth naming. Some mRNA cancer vaccines in trials are not personalized. They use shared cancer antigens found in many people's tumors. Those can be made in advance and given off the shelf. But they are still treatments for existing cancer, not prevention. The personalized versions are the ones built from a patient's own tumor mutations.

What is still unclear

The phase 2 melanoma data is promising but not final. Phase 3 trials are running now, and the field still has open questions.

• Which cancers will respond. Melanoma and some pancreatic cancer data exist, but many tumor types have not shown the same T cell response.
• Whether the vaccine alone is ever enough. Most trials pair it with checkpoint inhibitors, so the effect of the vaccine by itself is not well measured.
• How long protection lasts after surgery. Recurrence-free survival at 18 months is not the same as cure.
• Whether the six to eight week manufacturing window can shrink enough for patients who need treatment now.

Also, not every patient with cancer is eligible. In the melanoma trial, the tumor had to be fully resected and high risk. People with rapidly progressing, widely metastatic cancer were not the population in the strongest data so far.

If you already have a raw DNA file and want to look at inherited cancer risk markers, the free tool at HealthOS /dna reads a 23andMe, AncestryDNA, MyHeritage or whole-genome VCF file in the browser. 23andMe, AncestryDNA and MyHeritage files get single-variant findings such as HOXB13 and MUTYH; whole-genome VCFs are screened against ClinVar for the hereditary cancer panel. That is a different layer from the tumor sequencing behind these vaccines, but it is the layer you can check in your own file today.